FDA warns of recalled compounded drugs in Michigan

The Food and Drug Administration is warning doctors, veterinarians and patients to avoid certain sterile drugs distributed by the Specialty Medicine Compounding Pharmacy of Michigan.

The pharmacy, in South Lyon near Detroit, has recalled drugs distributed in Michigan between July 1 and Oct. 19. The company says no drugs were distributed outside the state.

The specialty pharmacy agreed to conduct the recall after finding floating particles in a sterile that came from a lot that may have been given to hospital patients. The FDA says it's unclear what the particles were.

The FDA recommends doctors and stop using drugs from the pharmacy immediately. For additional details, the public can contact the Specialty Medicine Compounding Pharmacy at 248-446-2643.

No have been reported in connection with the recall.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA: Georgia pharmacy recalling all sterile drugs

Mar 21, 2013

(AP)—The Food and Drug Administration says a Georgia compounding pharmacy that distributed a drug linked to eye infections is now recalling all of its injectable medicines following a federal inspection.

Indianapolis pharmacy recalls compounded drugs

Apr 23, 2013

(AP)—A pharmacy that makes specialty medications is recalling nearly 100 compounded drugs after federal regulators found potential safety problems during an inspection.

Fla. compounding pharmacy recalls sterile drugs

Apr 21, 2013

A Florida-based compounding pharmacy is voluntarily recalling all lots of its sterile non-expired drug products sold nationwide over concerns the products are not sterile and may contain bacteria.

US warns of mold in recalled specialty drugs

Mar 18, 2013

The U.S. Food and Drug Administration warned doctors and hospital managers Monday about a nationwide recall of all drugs made by a New Jersey compounding pharmacy because of possible mold contamination.

Recommended for you

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments